Anthropic has taken a new step to expand its activities in the life sciences and develop new therapies by opening an applied biology laboratory in the San Francisco Bay Area; an action that shows the company intends to take AI use beyond computational analyses and into real laboratory experiments.
According to ITna citing Reuters, Eric Kauderer-Abrams, Anthropic’s head of biosciences, confirmed the existence of the lab. He said the company conducts some of its work in on-site facilities and collaborates with external partners for other tasks. According to him, ultimately many advances in biology still require real laboratory experiments.
Anthropic later stated the lab is not specifically dedicated to drug discovery, but its establishment is part of the company’s broader program to operate in the life sciences.
Moving from simulation to real experiments
So far AI has been used in parts of biological research to analyze data, examine molecular structures, and perform calculations. These kinds of activities are mainly carried out in computer environments and are referred to as “in silico.”
But Anthropic’s move into laboratory activities signifies an effort to link AI’s computational capabilities with physical experiments. Kauderer-Abrams says laboratory automation is still in early stages, but it can make some research processes significantly faster.
Anthropic is also exploring using Claude to direct robotic units in conducting scientific experiments; an approach that could perform some repetitive laboratory tasks with less human involvement. However, the company stresses human oversight remains necessary to maintain safety.
Focusing on diseases that are unattractive to companies
In June 2026 Anthropic more formally announced its plans in the pharmaceutical sciences and said it intends to focus on preclinical research in areas that may be less financially attractive to traditional pharmaceutical companies.
The company hopes AI can accelerate the development process for some diseases that were previously difficult or even considered “untreatable.”
One area of interest is the design of bispecific and trispecific antibodies; molecules that can target multiple sites on proteins or cells. However, it is still unclear how much Anthropic’s programs in this area have led to practical, usable progress.
Anthropic is not currently conducting clinical trials. Any promising drug molecule must still undergo lengthy human testing and evaluation before reaching the market.
Claude enters a new phase of scientific research
The physical lab is not the only part of Anthropic’s plan to enter the life sciences. In June 2026 the company introduced Claude Science; an environment that brings together tools and software packages used by scientists in a single workspace and enables access to computational resources. Anthropic had said the program’s initial projects have a special focus on biology and biomedical research.
Anthropic has also expanded its collaborations with companies and researchers in the life sciences in recent months. The company says its goal is to use AI to accelerate scientific progress and that, in addition to biology, it is pursuing chemistry and other scientific fields in its programs.
In this vein, Anthropic in June published research on using Claude in biology and chemistry. The company has also worked on using AI agents to perform biological tasks and improving Claude’s performance in chemical analyses.
Acquiring a biotech startup
Anthropic’s expansion into the life sciences is not limited to internal development. According to Reuters, the company also acquired the startup Coefficient Bio in a stock deal worth about $400 million; a move that strengthens Anthropic’s capabilities in drug development.
Anthropic also added Vas Narasimhan, CEO of Novartis, to its board and has collaborations with major pharmaceutical companies including Roche’s Genentech, Bristol Myers Squibb, and Novo Nordisk on AI services and tools.
The company is recruiting specialists in areas such as procurement, laboratory operations, and characterization of proteins and nucleic acids to develop its laboratory activities. Anthropic’s stated goal is to substantially accelerate progress in the life sciences with the help of AI.
Automating the lab with robots
An important part of this program is combining AI models with laboratory equipment. In this approach, Claude can play a role in planning or directing parts of laboratory processes and robotic equipment can execute physical tasks.
In August Anthropic also introduced a hardware standard for its models to make AI interaction with physical equipment easier. This path could enable some repetitive processes to be carried out in the future with less human involvement, although the company emphasizes that laboratory automation is still at an early stage.
Alongside these activities, Anthropic has developed programs to give life science specialists access to its models. In September 2026 the company introduced the Life Sciences Verification Program, which provides life science professionals access to some Claude models for tasks such as drug discovery, research biology, and clinical development while implementing special protective mechanisms.
Expanding bioscience efforts amid safety concerns
Anthropic’s move toward biological experiments comes as there is wide debate about the increasing capabilities of AI models and the risk of their misuse.
Anthropic recently published reports about attempts to maliciously use Claude models, including in research related to biological weapons, and said it has identified and stopped some of these activities.
At the same time, some of the company’s researchers have warned about long-term AI risks. This issue has increased the importance of oversight and safety limits for work in fields like biology.
Anthropic itself has emphasized the importance of safety mechanisms in its new programs. The company’s special life sciences program is an example of efforts to provide broader access to powerful models while applying restrictions and oversight appropriate to the sensitivity of the field.
The trust challenge between Anthropic and drug companies
Anthropic’s expansion into pharmaceuticals creates another challenge: pharmaceutical companies’ trust in how their data are used.
Pharmaceutical companies may be concerned that collaborating with an AI company that also works with their competitors creates a risk of information leakage or indirect use of sensitive data. Anthropic says it keeps customer data segregated from one another.
The company has also drawn a boundary between its activities and those of pharmaceutical and biotech companies that focus directly on bringing drugs to market by not conducting clinical trials at this stage.
Overall, establishing a biology laboratory shows Anthropic is expanding AI’s role from analysis and data processing to direct interaction with scientific and laboratory processes. The success of this approach, however, will depend on the company’s ability to turn Claude’s computational achievements into reproducible laboratory results and ultimately real therapies.